RATIONALE: The use of cisplatin in patients with chronic kidney disease (CKD) is risky and depends on a number of factors. The optimal procedure in stage I of a non seminomatous germ cell tumor without proven lymphangioinvasion after orchiectomy is controversial and is the subject of a number of discussions due to the lack of randomized studies assessing individual treatment options. The adjuvant method of choice is surveillance or application of cisplatin-based chemotherapy with the risk of treatment related nephrotoxicity. Information about cisplatin safety in renal transplant patients is particularly limited. The aim of this paper is to share the experience with the application of adjuvant chemotherapy Bleomycin, Etoposide, Cisplatin (BEP) in high-risk patient with nonseminoma after kidney transplantation. PATIENT CONCERNS: We report a case report of rare group of high-risk patient with non-seminomatous germ cell testicular tumor (NSGCT) after kidney transplantation before application of adjuvant chemotherapy BEP. Patient presented with month-long discomfort in the scrotal area. Previously, he was treated with chronic kidney disease based on chronic glomerulonephritis, which was treated with repeated kidney transplantation. DIAGNOSIS: The ultrasound examination for a month-long discomfort in the scrotal area found a solid mass of the left testis. Radical inguinal orchiectomy confirmed NSGCT with the presence of lymphovascular invasion (LVI). Postoperative staging with computed tomography of the chest and abdomen did not show obvious dissemination of the disease. INTERVENTIONS: Reducing original dose of chemotherapeutics according to the recommendations of the summary of product characteristics led to only a transient increase in creatinine levels. OUTCOMES: The 5-year risk of relapse in surveillance was reduced to around 3% by applying cisplatin-based chemotherapy. LESSONS: Application of cisplatin-based chemotherapy is safe and effective in patients with CKD and in patients with a kidney transplant.

Department of Comprehensive Cancer Care Faculty of Medicine Masaryk University Kamenice

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute

Department of Pathology Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Radiation Oncology Masaryk Memorial Cancer Institute

Zobrazit více v PubMed

Tandstad T, Ståhl O, Håkansson U, et al. . One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol 2014;25:2167–72. PubMed

Divrik RT, Akdoğan B, Ozen H, Zorlu F. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified? J Urol 2006;176((4 pt 1)):1424–9. PubMed

National Comprehensive Cancer Network. Testicular Cancer (Version 1.2021). Available at: https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf. Accessed December 16, 2020.

EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam; 2020. ISBN 978–94-92671-07-3.

Ebewe Pharma Ges.m.b.H. Nfg. KG(2019) Cisplatin Ebewe 1 mg/ml Concentrate for Solution for Infusion SmPC. Available at: http://www.sukl.cz/modules/medication/detail.php?code=0189992&tab=texts (Accessed: March 20, 2017).[Article in Czech].

Albers P, Siener R, Kliesch S, et al. . Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003;21:1505–12. PubMed

Bokemeyer C, Köhrmann O, Tischler J, et al. . A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ’good-risk’ metastatic non-seminomatous germ cell tumors. Ann Oncol 1996;7:1015–21. PubMed

Horwich A, Sleijfer DT, Fosså SD, et al. . Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15:1844–52. PubMed

Ghazarian AA, Trabert B, Devesa SS, McGlynn KA. Recent trends in the incidence of testicular germ cell tumors in the United States. Andrology 2015;3:13–8. PubMed PMC

Pont J, Albrecht W, Postner G, et al. . Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996;14:441–8. PubMed

Cullen MH, Stenning SP, Parkinson MC, et al. . Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996;14:1106–13. PubMed

Travis LB, Fosså SD, Schonfeld SJ, et al. . Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354–65. PubMed

Van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. . Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007;25:4370–8. PubMed

Haugnes HS, Bosl GJ, Boer H, et al. . Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 2012;30:3752–63. PubMed

Goldstein RS, Mayor GH. Minireview. The nephrotoxicity of cisplatin. Life Sci 1983;32:685–90. PubMed

Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999;83:866–9. PubMed

Osiason AW, Polackwich RJ. Curative, platinum-based cytoxic drug therapy in a renal transplant recipient with metastatic testicular cancer. Cancer 1986;58:850–1. PubMed

Vogelzang NJ. Cisplatin and etoposide for metastatic testis cancer in a renal transplant recipient. J Urol 1990;143:1235–6. PubMed

Wood DP, Jr, Novick AC, Johnson DE, et al. . Treatment of metastatic transitional cell carcinoma following renal transplantation. Cleve Clin J Med 1989;56:61–3. PubMed

Droz JP, Chailley J, Kreis H. Germinal cell tumors of the testis (GCTT) in renal transplanted patients (RTP): report of two cases. Prog Clin Biol Res 1985;203:685–6. PubMed

Juric I, Basic-Jukic N. Testicular seminoma occurring after kidney transplantation in a patient previously treated for teratoma: de novo malignancy or recurrence in a different histologic form? Transplant Proc 2016;48:3128–9. PubMed